195 related articles for article (PubMed ID: 34696545)
41. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
Xu Y; Huang Z; Gong L; Fan Y
Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866
[TBL] [Abstract][Full Text] [Related]
42. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
43. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
44. Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma.
Yamaguchi M; Hirai S; Idogawa M; Sumi T; Uchida H; Fujitani N; Takahashi M; Sakuma Y
Exp Cell Res; 2023 May; 426(2):113570. PubMed ID: 36990421
[TBL] [Abstract][Full Text] [Related]
45. Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.
Iijima Y; Hirotsu Y; Mochizuki H; Amemiya K; Oyama T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Miyashita Y; Omata M
Clin Lung Cancer; 2018 Nov; 19(6):e843-e847. PubMed ID: 30122430
[No Abstract] [Full Text] [Related]
46. m
Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
[TBL] [Abstract][Full Text] [Related]
47. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
[TBL] [Abstract][Full Text] [Related]
48. [Comprehensive Genomic Analysis for Small Cell Lung Cancer].
Shibata Y; Udagawa H; Matsumoto S; Goto K
Gan To Kagaku Ryoho; 2021 Apr; 48(4):476-485. PubMed ID: 33976029
[TBL] [Abstract][Full Text] [Related]
49. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
[TBL] [Abstract][Full Text] [Related]
50. Small-cell lung cancer: an update on targeted therapies.
Joshi M; Ayoola A; Belani CP
Adv Exp Med Biol; 2013; 779():385-404. PubMed ID: 23288650
[TBL] [Abstract][Full Text] [Related]
51. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
52. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
[TBL] [Abstract][Full Text] [Related]
53. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
[TBL] [Abstract][Full Text] [Related]
54. A noteworthy treatment of metastatic small-cell lung cancer with afatinib, followed by subsequent development of rare metastatic lesions in the ascending and sigmoid colon.
Hsiao SC; Chen YH; Lo CC; Lin CI
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1243. PubMed ID: 32671978
[TBL] [Abstract][Full Text] [Related]
55. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
57. [Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].
Xie T; Li Y; Xing P
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):701-709. PubMed ID: 32758349
[TBL] [Abstract][Full Text] [Related]
58. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
[TBL] [Abstract][Full Text] [Related]
59. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.
Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W
Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178
[TBL] [Abstract][Full Text] [Related]
60. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
El Hussein S; Khader SN
Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
